EOJOAM
VKTX icon

E. Ohman J:or Asset Management’s Viking Therapeutics VKTX Stock Holding History

E. Ohman J:or Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$334K Sell
8,562
-3,554
-29% -$115K 0.01% 451
2026
Q1 		$394K Hold
12,116
– – 0.01% 432
2025
Q4 		$426K Buy
+12,116
New +$429K 0.01% 449

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

E. Ohman J:or Asset Management's VKTX Position: Q2 2026 in Review

E. Ohman J:or Asset Management reduced its Viking Therapeutics (VKTX) stake by 29% in Q2 2026, selling an estimated $115K and leaving 8,562 shares worth $334K. The position accounts for 0.01% of the portfolio, ranked #451.

E. Ohman J:or Asset Management first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $426K in Q4 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • E. Ohman J:or Asset Management held 8,562 shares of Viking Therapeutics worth $334K as of Q2 2026.
  • E. Ohman J:or Asset Management sold 3,554 Viking Therapeutics shares in Q2 2026, an estimated $115K.
  • Viking Therapeutics made up 0.01% of E. Ohman J:or Asset Management's portfolio in Q2 2026, its #451 holding.
  • E. Ohman J:or Asset Management first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • E. Ohman J:or Asset Management's Viking Therapeutics position peaked at $426K in Q4 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on E. Ohman J:or Asset Management's 13F filing for Q2 2026, filed 10 Jul 2026.